Vir Biotechnology
VIR
VIR
215 hedge funds and large institutions have $783M invested in Vir Biotechnology in 2024 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 75 increasing their positions, 73 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
215
Holders Change
+7
Holders Change %
+3.37%
% of All Funds
3.13%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
34
Increased
75
Reduced
73
Closed
24
Calls
$2.65M
Puts
$1.92M
Net Calls
+$732K
Net Calls Change
+$390K
Top Buyers
| 1 |
O
1
OrbiMed
New York
|
$20.6M |
| 2 |
2
JPMorgan Chase & Co
New York
|
$11.2M |
| 3 |
3
Millennium Management
New York
|
$11.1M |
| 4 |
4
Voloridge Investment Management
Jupiter,
Florida
|
$10.9M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$114M |
Top Sellers
| 1 |
1
Citadel Advisors
Miami,
Florida
|
$6.67M |
| 2 |
2
State Street
Boston,
Massachusetts
|
$45.3M |
| 3 |
3
Citigroup
New York
|
$755K |
| 4 |
BCM
4
Bridgeway Capital Management
Houston,
Texas
|
$7.02M |
| 5 |
5
Barclays
London,
United Kingdom
|
$4.83M |
